Zenosense, Inc. (ZENO) Set to Help Healthcare Providers Cont Zenosense, Inc. (ZENO) Set to Help Healthcare Providers Contain MRSA-Related Treatment Costs
In the United States, treatment costs of hospitalized MRSA patients run as high as $4.2 billion per year. For a patient who has an MRSA infection, a hospital stay is likely to be three times longer than one by an uninfected patient, at three times the cost. An MRSA-infected patient is also five times more likely to die than an uninfected party.
Zenosense, a healthcare technology company, is focused on developing a sensory device that detects MRSA bacterial contamination in patients. To that end, Zenosense has partnered with a respected sensor developer, Sgenia Group, to address this multibillion-dollar medical issue. The sensory device will function as a “smoke alarm” for MRSA, or uses an electronic nose to monitor and detect any airborne Volatile Organic Compounds (VOC) signature emitted by MRSA. It will be deployed for use in healthcare settings or other locations in which MRSA may pose a medical risk. By detecting MRSA in its early stages of development, healthcare providers will be able to minimize the heavy-handed costs of treatment associated with late-stage MRSA patient infection.
At present, there are devices for detection of incidences of this bacterial contamination, but they pose significant expense burdens for healthcare providers and are bulky in size, which minimizes advantages that could come with great setting mobility. Zenosense’s coming innovation, on the other hand, will be a wearable device, giving healthcare providers more flexibility in being able to deploy it to different patient locations with greater ease. On top of its advantage of mobility, the sensory device will make use of a technologically-potent, single sensor that has an advanced VOC-detecting capability equivalent to tens of thousands of sensors. While detection devices currently available cost around $8,000 each, Zenosense anticipates being able to manufacture the device at less than $100 per unit.
On top of MRSA detection, Zenosense has also extended its agreement with Sgenia Group to develop devices that detect VOC signatures given off by certain types of cancer, such as lung cancer. Current medical estimates show many cases of lung cancer being detected in its later stages, but earlier detection could lead to a patient cure rate of 70 percent.
For more information on the company visit www.zenosense.net
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com